---
title: "Sinopharm Accord's net profit attributable to shareholders for the first three quarters was 957 million yuan, a year-on-year decrease of 10.18%"
type: "News"
locale: "zh-HK"
url: "https://longbridge.com/zh-HK/news/262002608.md"
description: "Sinopharm Accord's performance report for the first three quarters of 2025 shows an operating income of 55.124 billion yuan, a year-on-year decrease of 2.38%; net profit attributable to the parent company is 0.957 billion yuan, a year-on-year decrease of 10.18%. The distribution segment's revenue is 40.594 billion yuan, with a net profit of 0.723 billion yuan, representing decreases of 0.59% and 7.32%, respectively. The retail segment's revenue is 15.226 billion yuan, with a net profit of 0.013 billion yuan, a year-on-year increase of 133.91%"
datetime: "2025-10-21T08:20:08.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/262002608.md)
  - [en](https://longbridge.com/en/news/262002608.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/262002608.md)
---

> 支持的語言: [简体中文](https://longbridge.com/zh-CN/news/262002608.md) | [English](https://longbridge.com/en/news/262002608.md)


# Sinopharm Accord's net profit attributable to shareholders for the first three quarters was 957 million yuan, a year-on-year decrease of 10.18%

According to the Zhitong Finance APP, Sinopharm Accord (000028.SZ) disclosed its performance report for the first three quarters of 2025. The company achieved an operating income of 55.124 billion yuan, a year-on-year decrease of 2.38%; the net profit attributable to shareholders of the listed company was 0.957 billion yuan, a year-on-year decrease of 10.18%, and the corresponding basic earnings per share decreased by 9.95% year-on-year.

From January to September 2025, the distribution segment achieved an operating income of 40.594 billion yuan, a year-on-year decrease of 0.59%; the net profit was 0.723 billion yuan, a year-on-year decrease of 7.32%. In the third quarter, the distribution business continued to face policy and market competition pressures, but the company stabilized and rebounded its distribution revenue through continuous optimization of its business structure. At the same time, due to the longer collection cycle of some downstream customers, the provision for credit impairment losses increased year-on-year, leading to a decline in profits. However, the company insisted on business adjustment and cost control, resulting in a narrowing of the profit decline. The retail segment achieved an operating income of 15.226 billion yuan, a year-on-year decrease of 7.14%; the net profit was 0.013 billion yuan, a year-on-year increase of 133.91%

### 相關股票

- [Sinopharm Accord (000028.CN)](https://longbridge.com/zh-HK/quote/000028.CN.md)

## 相關資訊與研究

- [Tennis-Sabalenka too hot for Osaka as the world number one reaches Indian Wells quarters](https://longbridge.com/zh-HK/news/278607881.md)
- [Tennis-Djokovic and Draper set up last-16 showdown, Siniakova ousts defending champion Andreeva](https://longbridge.com/zh-HK/news/278471601.md)
- [Tennis-Gauff retires from Indian Wells match due to elbow pain](https://longbridge.com/zh-HK/news/278312995.md)
- [Tennis-Californian Tien relishes full-circle moment at Indian Wells](https://longbridge.com/zh-HK/news/278308452.md)
- [Bank of America Securities Keeps Their Buy Rating on Contemporary Amperex Technology Co., Limited Class H (3750)](https://longbridge.com/zh-HK/news/278636079.md)